Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients

Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients In Vivo

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03037840

Enrollment

200

Registered

2017-01-31

Start date

2018-12-31

Completion date

2020-06-30

Last updated

2018-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

RF EMF, In Vivo, tumor specific frequencies

Brief summary

Studies have shown that tumor specific amplitude-modulated frequencies of radiofrequency electromagnetic fields that is associated with biofeedback upon exposure to in cancer patients. However, such discovery in other cancer patients are rare. And whether tumor specific frequencies can be found in Asian cancer patients remains unclear. The purpose of this study is to detect the tumor specific frequencies of Asian cancer patients in vivo.

Detailed description

The measurements were safety guaranteed and were conducted in hospital. Before detecting, the patient will be already diagnosed with cancer. The doctor and the operator are responsible for the detecting. When cancer patients are exposure to the RF electromagnetic fields, the radial pulse amplitude, blood pressure, skin electrical resistance and breath will be monitored. Biofeedback parameters will be recorded at different modulation frequencies and analyzed in order to find the variation and tumor specific frequencies.

Interventions

DEVICELow intensity amplitude-modulated RF EMFs

Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of cancer Disease

Exclusion criteria

* other patients

Design outcomes

Primary

Measure	Time frame
Biofeedback response of cancer patients at the exposure of Low intensity amplitude-modulated radiofrequency electromagnetic fields	within 20 min of exposure

Secondary

Measure	Time frame
Representation of autonomous response during the exposure of tumor specific frequencies modutated RF eletromagnetic fields	within 20 min of exposure

Contacts

Primary ContactXin Sherman Xuegang, professor

xxg@smu.edu.cn008613602733465

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026